The 12 Hallmarks of Aging in Dogs, Explained
Read full insightFeliAIM: The AIM Drug for Cat Kidney Disease
Where Toru Miyazaki's AIM injection stands in Japan, what the cat studies found, when it could reach the US, and what helps a cat with kidney disease now.
As Seen On
Hollywood Elixir® Senior Cat Supplement
17 science-backed actives
From$50/moSave up to 47%Save up to 44%Shop Now
Contents
FeliAIM at a glance
- What it is
- A lab-made AIM protein drug for chronic kidney disease in cats
- Developer
- IAM CAT and the Institute for AIM Medicine, led by Toru Miyazaki
- Status in Japan
- Filed April 24, 2026; no approval announced as of November 2026
- In the US
- Not available; no US application announced
- Is it a vaccine?
- No; it supplies a protein instead of training the immune system
- How it's given
- Expected to be an injection into a vein at a vet clinic
- Best evidence
- 11 treated cats: about 80% alive at 360 days, against 20% of 15 untreated cats
- Price
- Not announced
FeliAIM, AIM foods and today's kidney care compared
| FeliAIM | AIM-branded foods and supplements | Today's kidney care | |
|---|---|---|---|
| What it is | Lab-made AIM protein | Food or supplement using the AIM name | Renal diet plus drugs matched to the stage |
| Contains AIM? | Yes | No; some add L-cystine | No |
| How it's given | Expected injection into a vein at a clinic | Eaten | Diet at home; most drugs by mouth |
| Evidence in cats with kidney disease | 11-cat exploratory study; larger trial unpublished | Not confirmed in clinical studies | Renal diets shown to prolong survival |
| Status | Filed in Japan, April 2026 | Sold as food | Available now |
Competitor label and pricing facts checked November 11, 2026. Sources are listed in the References section below.
Sources and further detail
- Institute for AIM Medicine (24 April 2026), *Notice of the manufacturing and marketing approval application for the AIM cat drug FeliAIM* (in Japanese)
- Institute for AIM Medicine (13 June 2025), *The clinical trial for the AIM cat medicine has begun*
- Institute for AIM Medicine, *News* (in Japanese, checked 10 November 2026)
- Ministry of Agriculture, Forestry and Fisheries, National Veterinary Assay Laboratory, *Approval and review information* (in Japanese, checked November 2026)
- Tezuka T, Arakawa H, Kudo K et al. *The Veterinary Journal* (2026). A clinical impact of apoptosis inhibitor of macrophage on feline chronic kidney disease
- Sugisawa R, Hiramoto E, Matsuoka S et al. *Scientific Reports* (2016). Impact of feline AIM on the susceptibility of cats to renal disease
- Miyazaki T, Hirokami Y, Matsuhashi N et al. *Journal of Experimental Medicine* (1999). Increased susceptibility of thymocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor
- EDAILY (2 Sept 2026), "My cat will live to be 30?" The truth behind the buzz surrounding a new Japanese drug
- AFP via Free Malaysia Today (27 April 2026), Japan startup seeks approval of cat kidney disease treatment
- Neko no Kimochi, Benesse (updated 20 Oct 2025), *Interview with the developer of the new AIM drug for cats* (in Japanese)
- Noah Animal Hospital Group, *AIM: a complete guide* (in Japanese, as of July 2026)
- Felissimo Nekobu (18 March 2023), *Talk event with Toru Miyazaki, part 2* (in Japanese)
- University of Tokyo (9 Jan 2020), *Aiming to double cats' lifespan*
- Tokyo Shimbun (29 Jan 2023), *Extending cats' lives to 30: a kidney drug nears completion* (in Japanese)
- Taylor S, Finch N, Caney S et al. *Journal of Feline Medicine and Surgery* (2026). 2026 iCatCare consensus guidelines on the diagnosis and management of chronic kidney disease in cats
- dvm360 (24 May 2018), *FDA approves first drug for systemic hypertension in cats*
- The Vanguard Report (updated 28 Jan 2025), *New medical breakthrough means cats could live till 30 years old*
- FDA (14 March 2025), *FDA conditionally approves drug for management of ventricular hypertrophy in cats*
- FDA, *FDA regulation of animal drugs*







